Article

Five Considerations for Redesigning Clinical Trials to Better Target Patient Populations

The more committed life sciences companies are to clinical diversity, the better treatment options they will be able to offer.

Scientific and technological advances are making it easier than ever for life sciences companies to expand clinical trial candidate bases, so, in many cases, they should be able to more accurately reflect their real-world patient population. Learn 5 key considerations for assessing and restructuring clinical trial design and processes to achieve better representation of target populations.

  1. Use technology to expand recruitment
  2. Decide who is included and excluded - and why
  3. Align the diversity of the population with the clinical trial phase
  4. Consider the regulatory landscape and target markets
  5. Reevaluate your company's level of responsibility

By Vijaya Prajwala, Liisa M. Eisenlohr, and Enno Behrendt.

This byline originally appeared in Applied Clinical Trials Online.

Enno Behrendt, Associate Director

RELATED INDUSTRIES
MORE ON THIS TOPIC

Let us guide you

Guidehouse is a global advisory, technology, and managed services firm delivering value to commercial businesses and federal, state, and local governments. Serving industries focused on communities, energy, infrastructure, healthcare, financial services, defense, and national security, Guidehouse positions clients for AI-led innovation, efficiency, and resilience.

Stay ahead of the curve with news, insights and updates from Guidehouse about issues relevant to your organization and its work.